How Pragmatic Can Post-Approval Safety Trials Be?
This article was originally published in RPM Report
The February 23 meeting of the Pulmonary Allergy Drugs Advisory Committee included an interesting colloquy on the potential use of pragmatic trials to answer real-world use and safety questions. FDA Division of Pulmonary, Allergy and Rheumatology Director Badrul Chowdhury began the discussion by questioning a reference to “pragmatic trials” by the Chari of the committee, Jerry Krishnan (University of Illinois Hospital & Health Sciences System).
You may also be interested in...
FDA is joining the government’s bioresponse and defense efforts to develop small, mobile, on-demand manufacturing systems as next-tech solutions to dwindling domestic supply sources for essential drugs.
How should FDA make sure new safety information gets widely disseminated – especially against a history of many communications that have not shown the sustained ability to reach the most active prescribers? The agency got an earful of suggestions from the most recent safety review of the asthma/allergy drug montelukast.